<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02757872</url>
  </required_header>
  <id_info>
    <org_study_id>2014-3778</org_study_id>
    <secondary_id>R01DK102952</secondary_id>
    <nct_id>NCT02757872</nct_id>
  </id_info>
  <brief_title>Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives</brief_title>
  <official_title>Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial&#xD;
      in 25,875 US men and women investigating whether taking dietary supplements of vitamin D3&#xD;
      (2000 IU) or omega-3 fatty acids (Omacor (R) fish oil, 1 gram) reduces the risk of developing&#xD;
      cancer, heart disease, and stroke in people who do not have a prior history of these&#xD;
      illnesses. The VITAL Kidney Function in Hypertension ancillary study will evaluate the&#xD;
      effects of vitamin D or omega-3 fatty acids on kidney function among participants with&#xD;
      baseline hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This ancillary study to the VITamin D and OmegA-3 TriaL (VITAL) will test whether vitamin D3,&#xD;
      omega-3 fatty acids, or both prevent the development and progression of kidney disease in&#xD;
      participants with hypertension. Persons with hypertension are at high risk of kidney disease.&#xD;
&#xD;
      Vitamin D and omega-3 fatty acids are promising interventions for kidney disease prevention&#xD;
      and treatment, based on results of animal-experimental models and early human studies.&#xD;
      Because these interventions are relatively safe, inexpensive, and widely available, they may&#xD;
      offer opportunity to substantially reduce the burden of kidney disease in large populations.&#xD;
      This VITAL ancillary study will test whether vitamin D3 and/or omega-3 fatty acids prevent&#xD;
      loss of glomerular filtration rate, over 4 years of therapy.&#xD;
&#xD;
      In VITAL, 25,875 participants have been randomly assigned in a 2x2 factorial design to&#xD;
      vitamin D3 (cholecalciferol) 2000 IU daily versus placebo, and to eicosapentaenoic acid 465&#xD;
      mg plus docosahexaenoic acid 375 mg daily versus placebo, and followed for a mean of 5 years&#xD;
      to assess effects on cardiovascular disease and cancer events. This ancillary study will&#xD;
      identify and recruit a sub-cohort of VITAL participants with hypertension at baseline and&#xD;
      ascertain effects of study interventions on glomerular filtration rate in this group. Blood&#xD;
      samples will be collected at year 4 simultaneously for measurement of estimated glomerular&#xD;
      filtration rate (using serum creatinine and cystatin C) and other relevant biomarkers. This&#xD;
      VITAL ancillary study is designed to determine whether vitamin D3 and/or omega-3 fatty acids&#xD;
      have causal and clinically relevant effects on the development and progression of kidney&#xD;
      disease in hypertensives.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in estimated glomerular filtration rate</measure>
    <time_frame>4 years</time_frame>
    <description>Serum creatinine and cystatin C measurement pre-randomization and year 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Albuminuria</measure>
    <time_frame>4 years post-randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2612</enrollment>
  <condition>Hypertension</condition>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Vitamin D and fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary Supplement: Vitamin D Vitamin D3 (cholecalciferol), 2000 IU per day. Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D and fish oil placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary Supplement: Vitamin D Vitamin D3 (cholecalciferol), 2000 IU per day. Dietary Supplement: Fish oil placebo Fish oil placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D placebo and fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).&#xD;
Dietary Supplement: Vitamin D placebo Vitamin D3 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D placebo and fish oil placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dietary Supplement: Vitamin D placebo Vitamin D3 placebo Dietary Supplement: Fish oil placebo Fish oil placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 (cholecalciferol), 2000 IU per day</description>
    <arm_group_label>Vitamin D and fish oil</arm_group_label>
    <arm_group_label>Vitamin D and fish oil placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 Fatty acids</intervention_name>
    <description>Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])</description>
    <arm_group_label>Vitamin D and fish oil</arm_group_label>
    <arm_group_label>Vitamin D placebo and fish oil</arm_group_label>
    <other_name>Fish oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 placebo</intervention_name>
    <description>Vitamin D3 placebo</description>
    <arm_group_label>Vitamin D placebo and fish oil</arm_group_label>
    <arm_group_label>Vitamin D placebo and fish oil placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil placebo</intervention_name>
    <description>Fish oil placebo</description>
    <arm_group_label>Vitamin D and fish oil placebo</arm_group_label>
    <arm_group_label>Vitamin D placebo and fish oil placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants in VITAL (NCT 01169259) with a self-reported physician diagnosis of&#xD;
             hypertension are eligible to participate in this ancillary study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of diabetes mellitus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michal L Melamed, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 28, 2016</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Kidney Diseases</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Omega 3 fatty acids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

